Somatostatin analogue pasireotide (SOM230) inhibits catecholamine secretion in human pheochromocytoma cells
| Autor: | Laura Streit, Didier Mutter, Sylvain Hugel, Sophie Moog, Stéphanie Lacomme, Virginie Andry, Claire Nomine-Criqui, Nicolas Vitale, Marion Rame, Michel Vix, Herbert A. Schmid, Stéphane Ory, Stéphane Gasman, Emeline Tanguy, Yannick Goumon, Laurent Brunaud, Florence Bihain, Sandra Lomazzi |
|---|---|
| Přispěvatelé: | Institut des Neurosciences Cellulaires et Intégratives (INCI), Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), Centre de Ressources Biologiques - [Nancy] (CRB Nancy), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy) |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Cancer Research
medicine.medical_specialty endocrine system Adrenal Gland Neoplasms Octreotide 030209 endocrinology & metabolism [SDV.CAN]Life Sciences [q-bio]/Cancer Pheochromocytoma Neuroendocrine tumors 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Catecholamines Internal medicine Cell Line Tumor medicine Humans Secretion business.industry medicine.disease Pasireotide 3. Good health Neuroendocrine Tumors Endocrinology medicine.anatomical_structure Somatostatin Oncology chemistry 030220 oncology & carcinogenesis Catecholamine business Adrenal medulla medicine.drug |
| Zdroj: | Cancer Letters Cancer Letters, Elsevier, 2021, ⟨10.1016/j.canlet.2021.10.009⟩ |
| ISSN: | 0304-3835 |
| DOI: | 10.1016/j.canlet.2021.10.009⟩ |
| Popis: | International audience; Increasingly common, neuroendocrine tumors (NETs) are regarded nowadays as neoplasms potentially causing debilitating symptoms and life-threatening medical conditions. Pheochromocytoma is a NET that develops from chromaffin cells of the adrenal medulla, and is responsible for an excessive secretion of catecholamines. Consequently, patients have an increased risk for clinical symptoms such as hypertension, elevated stroke risk and various cardiovascular complications. Somatostatin analogues are among the main anti-secretory medical drugs used in current clinical practice in patient with NETs. However, their impact on pheochromocytoma-associated catecholamine hypersecretion remains incompletely explored. This study investigated the potential efficacy of octreotide and pasireotide (SOM230) on human tumor cells directly cultured from freshly resected pheochromocytomas using an implemented catecholamine secretion measurement by carbon fiber amperometry. SOM230 treatment efficiently inhibited nicotine-induced catecholamine secretion both in bovine chromaffin cells and in human tumor cells whereas octreotide had no effect. Moreover, SOM230 specifically decreased the number of exocytic events by impairing the stimulation-evoked calcium influx as well as the nicotinic receptor-activated inward current in human pheochromocytoma cells. Altogether, our findings indicate that SOM230 acts as an inhibitor of catecholamine secretion through a mechanism involving the nicotinic receptor and might be considered as a potential anti-secretory treatment for patients with pheochromocytoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect